Clinical-stage rare disease therapeutics

Where compassion
becomes medicine.

Noriva Therapeutics develops novel therapies for patients with devastating disease and no approved treatment — built on clinical evidence, driven by human urgency.

"Some patients suffer in ways medicine has no answer for.
Noriva was founded by a physician who refused to accept that."

Noriva Therapeutics was born at the bedside — from a physician's firsthand witness of suffering in patients with devastating disease and no path forward. Moved by the depth of that suffering, our founder pursued years of rigorous clinical investigation, developing an innovative therapeutic approach grounded in evidence and driven by compassion. That founding conviction shapes everything we build.

What we are

A company built on evidence, designed for impact.

Noriva develops therapeutic platforms for rare diseases where no approved options exist — pursuing regulatory clarity and meaningful outcomes for the patients who need it most.

Clinical foundation
Our programs are grounded in rigorous real-world clinical evidence, built to meet the highest standards of regulatory science.
Rare disease focus
We work in indications with severe unmet need — diseases that have waited too long for a real answer.
Regulatory rigor
From preclinical design to IND submission, every program is built with regulatory precision from day one.
Get in touch

Contact Us

For partnership, regulatory, business development, or clinical inquiries